Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Global Partners Declares Second-Quarter 2025 Cash Distribution of $0.7500 on Common Units
08:30am, Friday, 25'th Jul 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that the Board of Directors of its general partner, Global GP LLC, has
West Pharma Lifts Outlook On Surging GLP-1 Demand, Stock Soars
10:38am, Thursday, 24'th Jul 2025
West Pharmaceutical Services, Inc. WST shares are surging Thursday after the injectable pharmaceutical packaging and delivery systems company delivered a robust beat on its second-quarter 2025 earning
Global Partners LP to Host Second-Quarter 2025 Financial Results Conference Call on August 7, 2025
08:30am, Thursday, 24'th Jul 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that it will release its second-quarter 2025 financial results before t
Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry
09:25am, Wednesday, 23'rd Jul 2025
The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effects DehydraTECH reduces side effects and could support patient re
Weight loss drugs could be a gamechanger for women with a common hormonal disorder
08:00am, Sunday, 20'th Jul 2025
Several women who have reported improvements in symptoms of polycystic ovary syndrome, a common hormonal disorder, after using GLP-1s such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Patients a
Global Partners Announces Cash Distribution on Series B Preferred Units
08:35am, Monday, 14'th Jul 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (the “Partnership”) today announced that the Board of Directors (the “Board”) of its general partner, Global GP LLC, has declare
Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies
09:30am, Thursday, 10'th Jul 2025
Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies
Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
10:56am, Friday, 04'th Jul 2025
NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.
Viking: I'm Bullish On Oral/Injectable GLP-1 Obesity Data Catalysts
03:05pm, Thursday, 03'rd Jul 2025
VK2735 shows strong early weight-loss data, positioning Viking as a potential third major player in the booming GLP-1 obesity drug market. Despite a sharp stock decline, Viking is well-funded, with $8
This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk
09:14pm, Tuesday, 01'st Jul 2025
There are a lot of healthcare companies that are investing in GLP-1 weight loss drugs. Today, the leaders in that space are Eli Lilly and Novo Nordisk.
Hims & Hers Can Still Thrive Without GLP-1s
02:27pm, Tuesday, 01'st Jul 2025
Hims & Hers has achieved explosive revenue and subscriber growth, driven by its direct-to-consumer telehealth model and expanding product lines. The recent termination of the Novo Nordisk partnership
SAN FRANCISCO and SUZHOU, China, June 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial
Dario Unveils Groundbreaking GLP-1 and AI-Personalization Digital Health Findings
08:30am, Tuesday, 24'th Jun 2025
Dario's new research shows sustained outcomes post-GLP-1 for platform users and 89% accuracy in innovative AI blood glucose prediction; the Company is actively working to leverage these findings in co
12 of 13 participants maintained or lost weight at 3 months, with 6 of 13 losing additional weight after stopping GLP-1 therapy and undergoing Revita procedure
New findings demonstrated that a single dose of Rejuva was well tolerated in healthy animals, with no evidence of toxicity
